
Pierre Fabre announces investments and partnerships in lung cancer research
Ella Day | March 27, 2025 | News story | Research and Development |Â Â Oncology, Pierre Fabre Laboratories, lung cancer treatment, oncologyÂ
Pierre Fabre Laboratories has announced investment and partnership plans to improve the lives of lung cancer patients with unmet needs.
The pharma and cosmetics company dedicates 80% of its research and development budget to oncology, as part of its focus on targeted therapies. It has over a decade of experience in lung cancer research.
It will present interim data from its OCTOPUS study which investigates the effectiveness of treatments and quality of life in routine practice for patients with BRAFV600E mutant metastatic non-small cell lung cancer (mNSCLC). This will take place at the European Lung Cancer Congress (ELCC) on 26 to 29 March in Paris, France. Additional efficacy data will be shared at the congress.
Pierre Fabre Laboratories seeks to introduce new and approved therapies to patients. The company is expanding access to Braftovi (encorafenib) plus Mektovi (binimetinib) in mNSCLC globally.
Additionally, it is partnering with Scorpion Therapeutics to support its development of targeted therapies. Both will research epidermal growth factor receptor (EGFR) mutant NSCLC in patients who have developed resistance to other targeted therapies, which is an increasingly unmet medical need.
Its acquisition of Vertical Bio is also accelerating the development of a monoclonal antibody targeting c-MET, known as PFL-002/VERT-002.
Ella Day
27/3/25
Related Content

Rethinking oncology trial endpoints with generalised pairwise comparisons
For decades, oncology trials have been anchored to a familiar set of endpoints. Overall survival …

Pharma&’s ovarian cancer therapy approved for use by NHS Scotland
Pharma& has announced that its treatment for ovarian cancer, Rubraca (rucaparib), has been accepted by …

Bio-Rad signs exclusive European distribution deal with Gencurix for oncology testing kits
The agreement expands access to oncology testing kits across Europe






